Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Increases By 600.2%

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 379,500 shares, a growth of 600.2% from the March 31st total of 54,200 shares. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is currently 0.3 days. Currently, 4.4% of the company’s shares are sold short.

Insider Activity at Xilio Therapeutics

In other Xilio Therapeutics news, major shareholder Gilead Sciences, Inc. purchased 485,250 shares of the business’s stock in a transaction on Tuesday, April 2nd. The shares were purchased at an average cost of $0.76 per share, for a total transaction of $368,790.00. Following the acquisition, the insider now owns 7,345,473 shares of the company’s stock, valued at $5,582,559.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Xilio Therapeutics

An institutional investor recently bought a new position in Xilio Therapeutics stock. PFG Investments LLC bought a new stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned about 0.09% of Xilio Therapeutics at the end of the most recent reporting period. 54.29% of the stock is owned by hedge funds and other institutional investors.

Xilio Therapeutics Price Performance

Shares of NASDAQ:XLO traded down $0.07 during trading on Thursday, reaching $0.99. 170,113 shares of the stock were exchanged, compared to its average volume of 1,033,655. Xilio Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.40. The stock has a fifty day moving average of $0.90 and a two-hundred day moving average of $1.03. The firm has a market cap of $34.13 million, a price-to-earnings ratio of -0.38 and a beta of -0.12.

Xilio Therapeutics (NASDAQ:XLO) last issued its earnings results on Monday, April 1st. The company reported ($0.64) earnings per share for the quarter. Sell-side analysts forecast that Xilio Therapeutics will post -1.53 EPS for the current year.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.